Iovance Biotherapeutics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Iovance Biotherapeutics kazanç ve gelirin sırasıyla yıllık 67.1% ve 45.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 66.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -27.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

67.1%

Kazanç büyüme oranı

66.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	45.3%
Gelecekteki özkaynak getirisi	-27.7%
Analist kapsamı	Good
Son güncelleme	11 Nov 2024

Gelecekteki son büyüme güncellemeleri

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Aug 11

Recent updates

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Aug 11

Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Aug 11

Iovance Biotherapeutics: Amtagvi Launch Continues Upward

Jun 26

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

May 10

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Apr 09

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Mar 25

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Feb 20

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Jan 19

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Sep 27

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Aug 25

Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Aug 25

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

Aug 04

Iovance: TIL Cell Therapy Set To Prove Itself

Jul 11

Iovance: Onward To Approval

Apr 20

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Mar 25

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:IOVA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	739	-59	53	92	10
12/31/2025	460	-249	-155	-158	13
12/31/2024	162	-361	-280	-238	13
9/30/2024	91	-410	-374	-364	N/A
6/30/2024	33	-440	-400	-389	N/A
3/31/2024	2	-450	-405	-384	N/A
12/31/2023	1	-444	-384	-362	N/A
9/30/2023	1	-433	-377	-356	N/A
6/30/2023	0	-419	-355	-335	N/A
3/31/2023	N/A	-412	-333	-319	N/A
12/31/2022	N/A	-396	-313	-293	N/A
9/30/2022	N/A	-390	-294	-269	N/A
6/30/2022	N/A	-376	-296	-263	N/A
3/31/2022	N/A	-358	-278	-239	N/A
12/31/2021	N/A	-342	-266	-228	N/A
9/30/2021	N/A	-311	-290	-237	N/A
6/30/2021	N/A	-284	-281	-220	N/A
3/31/2021	N/A	-265	-259	-202	N/A
12/31/2020	N/A	-260	-252	-205	N/A
9/30/2020	N/A	-255	-223	-196	N/A
6/30/2020	N/A	-246	-208	-198	N/A
3/31/2020	N/A	-230	-202	-195	N/A
12/31/2019	N/A	-198	-166	-159	N/A
9/30/2019	N/A	-167	-140	-137	N/A
6/30/2019	N/A	-151	-125	-122	N/A
3/31/2019	N/A	-134	-114	-112	N/A
12/31/2018	N/A	-124	-102	-101	N/A
9/30/2018	N/A	-117	-92	-91	N/A
6/30/2018	N/A	-105	N/A	-84	N/A
3/31/2018	N/A	-98	N/A	-78	N/A
12/31/2017	N/A	-92	N/A	-79	N/A
9/30/2017	N/A	-82	N/A	-70	N/A
6/30/2017	N/A	-128	N/A	-61	N/A
3/31/2017	N/A	-116	N/A	-47	N/A
12/31/2016	N/A	-102	N/A	-33	N/A
9/30/2016	N/A	-95	N/A	-27	N/A
6/30/2016	N/A	-34	N/A	-19	N/A
3/31/2016	N/A	-29	N/A	-19	N/A
12/31/2015	N/A	-28	N/A	-18	N/A
9/30/2015	N/A	-24	N/A	-15	N/A
6/30/2015	N/A	-19	N/A	-13	N/A
3/31/2015	N/A	-15	N/A	-10	N/A
12/31/2014	N/A	-12	N/A	-9	N/A
9/30/2014	N/A	-27	N/A	-8	N/A
6/30/2014	N/A	-34	N/A	-6	N/A
3/31/2014	N/A	-35	N/A	-6	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IOVA önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: IOVA önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: IOVA önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: IOVA şirketinin gelirinin (yıllık 45.3% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: IOVA şirketinin gelirinin (yıllık 45.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IOVA 3 yıl içinde kârsız olması bekleniyor.

Iovance Biotherapeutics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Forecast to breakeven in 2026

Consensus revenue estimates increase by 11%

Price target increased by 19% to US$24.42

Consensus revenue estimates decrease by 25%

Price target decreased by 8.7% to US$20.42

Recent updates

Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity

Iovance Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Iovance Biotherapeutics: Moving To The Next Phase

Iovance Therapeutics: Historic Product, Tough Commercial Outlook

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Iovance Biotherapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 3000 Value Index

Iovance Biotherapeutics, Inc. Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics: Amtagvi Launch Continues Upward

Iovance Biotherapeutics, Inc. Elects Frederick G. Vogt as Director

Forecast to breakeven in 2026

New minor risk - Financial position

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

Iovance Biotherapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Iovance Biotherapeutics, Inc. Agrees to A Proposed Settlement

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Consensus revenue estimates increase by 11%

Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer

New minor risk - Profitability

Iovance Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

New major risk - Share price stability

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Price target increased by 19% to US$24.42

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Consensus revenue estimates decrease by 25%

Iovance Biotherapeutics, Inc.’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

New minor risk - Profitability

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Iovance Biotherapeutics, Inc. Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

Price target decreased by 8.7% to US$20.42

Consensus revenue estimates decrease by 71%

Iovance Biotherapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Financial position

Independent Director recently bought US$27m worth of stock

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Updates

Price target decreased by 8.9% to US$22.36

Consensus revenue estimates decrease by 62%, EPS upgraded

New minor risk - Financial position

Iovance Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Shareholder dilution

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Price target increased by 13% to US$24.55

Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma

Consensus revenue estimates decrease by 21%, EPS upgraded

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Accepts the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Consensus revenue estimates increase by 1,282%, EPS downgraded

Consensus revenue estimates decrease by 84%, EPS upgraded

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited fo

Interim CEO exercised options and sold US$234k worth of stock

Chief Medical Officer exercised options and sold US$67k worth of stock

Price target decreased to US$23.00

Independent Director recently bought US$62k worth of stock

Independent Director recently bought US$65m worth of stock

Price target decreased to US$23.77

Independent Director recently bought US$62k worth of stock

Iovance Biotherapeutics, Inc. Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (Sitc) Annual Meeting

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iovance Biotherapeutics, Inc. Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte Therapy

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates